Depression & Suicide Risk

Major depressive disorder is among the most common mental disorders in the US: lifetime prevalence runs about 5–17% (averaging ~12%), roughly twice as common in women — the hormonal transitions of menstruation, pregnancy, postpartum, and menopause contribute — with a mean onset around age 40 and rising incidence in younger people associated with alcohol and drug use. It is a diagnosable illness, not a character weakness or a mood that willpower should fix.

The DSM-5 criteria give the syndrome its shape: at least five symptoms clustered within a two-week window, marking a change from the person’s usual self, and one of them has to be depressed mood or anhedonia (loss of interest or pleasure). The rest come largely from the neurovegetative cluster — the body-function symptoms: sleep disturbance (insomnia or hypersomnia), appetite and weight changes, fatigue, psychomotor retardation or agitation, and poor concentration — plus guilt or worthlessness and thoughts of death. Symptoms occur most of the day, nearly every day, and impair social or occupational functioning. Two rule-outs matter: any history of a manic or hypomanic episode makes the diagnosis bipolar disorder, not MDD, and children and adolescents may present with an irritable rather than depressed mood.

The natural course is why treatment matters: untreated episodes last 6 to 12 months, and recurrence risk climbs with each one — roughly 50% after a first episode, 70% after a second, 90% after a third. About 5–10% of patients with MDD eventually declare bipolar disorder, which is why new activity and talkativeness on an antidepressant is a watched-for finding, not good news.

The classic teaching is the monoamine hypothesis: depression reflects abnormalities in serotonin, norepinephrine, and dopamine signaling. The supporting evidence is pharmacologic — SSRIs and SNRIs work, and most antidepressants raise synaptic serotonin and/or norepinephrine. A finding that matters for this page specifically: people with suicidal ideation have been found to have low levels of serotonin metabolites.

The modern caveat: current theories hold that depression arises primarily from more complex neuroregulatory systems and neural circuits, with the neurotransmitter disturbances as a secondary, downstream consequence — low monoamines are part of the story, not the whole cause. Depressed patients also show lower GABA levels in plasma, CSF, and brain, glutamate and glycine involvement, and thyroid and growth-hormone abnormalities — and newer agents target glutamatergic and GABAergic pathways.

Upstream of the chemistry sit genes and stress. Twin studies show a very high concordance rate for MDD, particularly in monozygotic twins. And severe early stress — multiple adverse childhood experiences, trauma — can drastically alter neuroendocrine and behavioral responses and cause structural changes in the cerebral cortex; imaging in MDD shows increased subcortical hyperintensities and reduced left anterior brain metabolism. The circuit is: vulnerability plus stress reshapes neuroregulation, which disturbs the monoamines the drugs act on.

Suicide is not a rare complication of depression — it is the disease’s central danger. About two-thirds of individuals with MDD contemplate suicide, and about 10–15% die by suicide (StatPearls); an estimated 90% of people who complete suicide have a psychiatric disorder, most commonly a mood disorder. That is why suicide risk is evaluated at every visit — screening at each psychiatric encounter can lower suicide incidence. The demographics sharpen the picture: men die by suicide at about 4× the rate of women, adults over 85 have the highest age-specific rates, and firearms account for roughly 55% of US suicide deaths — the reason lethal-means counseling centers on them.

Risk factors split into static (history you cannot change: prior attempts — the strongest predictor — psychiatric diagnosis, family history of suicide, adverse childhood experiences, male sex, divorce, military service) and dynamic (what the nurse can intervene on: current depression, hopelessness, insomnia, agitation, intoxication, access to lethal means, recent psychosocial stressors). Dynamic factors are the working surface of nursing care.

First, dispel the myth that stops assessments from happening: asking directly about suicide does not increase risk or plant the idea — the evidence does not support that fear, and thoughtful, direct inquiry is a necessary part of risk assessment. The assessment then climbs a ladder: ideation (passive death wish vs. active thoughts — onset, frequency, intensity, triggers) → plan (the presence and specificity of a plan strongly correlate with the likelihood of a serious attempt) → intent (determination to act) → access to lethal means → lethality of the method → preparatory behaviors (researching methods, acquiring means) and prior attempts. Alongside risk, assess protective factors — social support, reasons for living, engagement in treatment, hopefulness — but never treat them as a counterweight that “cancels out” risk.

Antidepressants are slow: full effect usually takes 4 to 8 weeks, though some improvement can appear in the first 1–2 weeks, and patients may need to try several agents before one works. Crucially, recovery is staggered — problems with sleep, appetite, and concentration often improve before mood lifts (NIMH). A patient two weeks into therapy can be sleeping and eating again while still feeling as hopeless as the day treatment began.

Overlay the safety data on that same calendar and the teaching writes itself. All antidepressant classes carry an FDA boxed warning — reported by NIMH, StatPearls, and MedlinePlus — for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25, especially in the first few weeks after starting or after a dose change; the FDA advises that patients of all ages be watched closely during those first weeks. So the early-treatment window holds two sourced facts side by side: the body-function symptoms recover first while mood is still low, and this is exactly the period the FDA flags for the closest suicide-risk monitoring. For the nurse, “the medication is starting to work” never means “the danger has passed” — it marks the weeks when vigilance peaks.